
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Regenerative Peripheral Nerve Interface: A great option to prevent and decrease pain for patients with post-mastectomy pain syndrome
Outcomes from Kentucky Board of Pharmacy Board Authorized Protocols</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Regenerative Peripheral Nerve Interface: A great option to prevent and decrease pain for patients with post-mastectomy pain syndrome</strong><br><em>Outcomes from Kentucky Board of Pharmacy Board Authorized Protocols</em></summary>
            <div>
                <ul><li>- <b>Two separate study protocols</b>: (1) prospective cohort protocol evaluating <b>RPNI</b> for prevention/treatment of PMPS; (2) retrospective cohort evaluation of Kentucky <b>Board Authorized Protocols (BAPs)</b> for UTI, GAS, and COVID-19 treatment by pharmacists.</li><li>- Key study periods: RPNI enrollment planned <b>Dec 1, 2025 - Dec 30, 2030</b>; Kentucky BAP data window <b>Oct 1, 2022 - Sep 30, 2025</b>.</li><li>- Metadata: single-center (UK/UK Healthcare sites) prospective surgical cohort for RPNI; retrospective single-cohort EHR study across UK Pharmacist Care Clinic for BAPs.</li></ul>
                
        <details>
            <summary><strong>knowledge test</strong></summary>
            <div>
                <ul><li>- What is the reported prevalence range of PMPS after mastectomy? (answer: <q><b>35-60%</b></q>)</li><li>- By definition PMPS persists at least how long to be classified as chronic? (answer: <q><b>6 months</b></q>)</li><li>- Standard nitrofurantoin dosing in the UTI BAP is <q><b>100 mg</b></q> how often and for how long? (answer: <q><b>twice daily for 5 days</b></q>)</li><li>- Sample size per arm planned in the RPNI study to detect effect size 0.39 at 80% power is <q><b>100 patients</b></q>.</li><li>- Chosen comparator effectiveness for nirmatrelvir/ritonavir in the COVID-19 arm rounded for analysis is <q><b>80%</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Article 1: RPNI for Post-Mastectomy Pain Syndrome (PMPS)</strong><br><em>Prospective surgical cohort protocol</em></summary>
            <div>
                <ul><li>- Focus: evaluate <b><u>RPNI</u></b> to <b>prevent</b> PMPS and to <b>decrease</b> established PMPS pain levels in mastectomy patients.</li><li>- Rationale: PMPS is neuropathic, linked to peripheral nerve injury and sensitization; current treatments have inconclusive results.</li><li>- Primary design: prospective cohort with two aims (prevention arm and treatment arm), follow-up at <b>6 months</b>.</li></ul>
                
        <details>
            <summary><strong>Introduction & Pathophysiology</strong></summary>
            <div>
                <ul><li>- PMPS clinical picture: dull dragging, shooting neuropathic pain, numbness -> chest wall, axilla, ipsilateral arm.</li><li>- Mechanism: peripheral afferent sensitization + central sensitization ---> neuroma formation after sensory nerve injury.</li><li>- Key statistics: PMPS prevalence reported as <q><b>35-60%</b></q>; defined as pain present ≥ <q><b>6 months</b></q> and ≥ <q><b>50%</b></q> of the time.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Specific Aims & Hypotheses</strong></summary>
            <div>
                <ul><li>- Aim 1 (prevention): test if intraoperative <b>RPNI</b> at identified nerve endings prevents chronic neuropathic chest pain compared to no RPNI.</li><li>- Aim 1 hypothesis: patients with intraop RPNI will have <b>no or almost no neuropathic chest pain</b> vs controls.</li><li>- Aim 2 (treatment): test if RPNI reduces pain in patients with established PMPS when performed postoperatively.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Study population, recruitment & sample size</strong></summary>
            <div>
                <ul><li>- Target: breast cancer patients post unilateral or bilateral total skin-sparing mastectomy at UK hospitals.</li><li>- Sample per group: planned <q><b>100 patients</b></q> for prevention arm and <q><b>100 patients</b></q> for treatment arm to detect effect size <q><b>0.39</b></q> with <q><b>80%</b></q> power.</li><li>- Recruitment methods: EHR identification, clinic invitations, email, phone calls; informed consent in-person/phone/electronic.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Inclusion & Exclusion criteria</strong></summary>
            <div>
                <ul><li>- Inclusion: <b>female</b>, age > <q><b>18 years</b></q>, underwent unilateral or bilateral total skin-sparing mastectomy; either prophylactic RPNI or diagnosed PMPS and electing RPNI.</li><li>- Exclusion: males, pregnancy, prisoners, age < <q><b>18 years</b></q>, lack of consent, failure to meet inclusion.</li><li>- Note: procedure may be offered as standard of care even if not enrolled in study.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Intervention: Regenerative Peripheral Nerve Interface (RPNI)</strong></summary>
            <div>
                <ul><li>- Technique: wrap an autologous muscle graft (harvested from nearby <b><u>pectoralis</u> or <u>serratus</u></b>) around the transected nerve ending and suture in place.</li><li>- Purpose: provide a physiological target for regenerating axons to reduce neuroma formation and ectopic firing.</li><li>- Compared alternative: Targeted Muscle Reinnervation (TMR) also effective but requires nerve target and more microsurgical expertise.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Outcome measures & instruments</strong></summary>
            <div>
                <ul><li>- Primary PROs: SF-MPQ-2 total and item pain scores; single-item pain level (SF-MPQ-2 Q23) 0-10 scale.</li><li>- Function/satisfaction: BREAST-Q Physical Well-Being: Chest (PWBC) score (range 0-100; higher = better).</li><li>- Objective exam (Aim 2): Tinel’s sign and <b>pressure algometry</b> at standardized chest sites to measure mechanical pain threshold (kg or N).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Timing of assessments & follow-up</strong></summary>
            <div>
                <ul><li>- Aim 1: single survey at <q><b>6 months</b></q> post-mastectomy/RPNI assessing pain and function.</li><li>- Aim 2: baseline pre-op survey (~<q><b>2 weeks</b></q> pre-RPNI) and follow-up at <q><b>6 months</b></q> post-RPNI with blinded clinical exam.</li><li>- Data recorded with de-identified codes in secured systems.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Data collection variables</strong></summary>
            <div>
                <ul><li>- Demographics: age, gender, smoking, comorbidities; cancer: stage, reconstruction type.</li><li>- Surgical details: date of mastectomy, RPNI description/location, nerve(s) treated, time to last follow-up.</li><li>- Medication and healthcare utilization: pain meds, duration, clinic visits.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Statistical analysis plan</strong></summary>
            <div>
                <ul><li>- Continuous data: mean (SD); between-group comparisons via <b>t-test</b>; paired pre-post via <b>paired t-test</b> for Aim 2.</li><li>- Categorical data: frequencies/percentages; chi-square or Fisher's exact test.</li><li>- Multivariable adjustment: multiple regression to control confounders; significance at <q><b>P &lt; 0.05</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Bias mitigation & blinding</strong></summary>
            <div>
                <ul><li>- Use explicit inclusion/exclusion criteria to reduce selection bias.</li><li>- Standardized surveys and tools to minimize measurement bias.</li><li>- Clinical evaluator blinded to group and timing to reduce observer bias.</li><li>- Predefined outcomes and analysis plan to limit reporting bias.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Ethical, safety & retention strategies</strong></summary>
            <div>
                <ul><li>- IRB review planned; informed consent required; standard clinical safety protocols for surgery.</li><li>- Retention: reminders (phone/email/MyChart), flexible scheduling, summary of findings, and modest compensation.</li><li>- Adverse events: documented and managed promptly; procedure available as standard care even if patient declines study participation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Potential pitfalls & common misunderstandings</strong></summary>
            <div>
                <ul><li>- PMPS heterogeneity: neuropathic vs nociceptive features may coexist ---> RPNI targets neuropathic neuroma pain, not all chest wall pain.</li><li>- Expectation bias: surgical patients may report placebo-related improvements; need blinded assessor and objective algometry.</li><li>- Generalizability: single-center and surgical expertise may limit external validity.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Supporting evidence & prior outcomes</strong></summary>
            <div>
                <ul><li>- Existing literature: small case series report symptom reduction after intercostal nerve RPNI for PMPS; data limited but positive (see cited case reports).</li><li>- RPNI established for post-amputation pain control in lower extremity with favorable outcomes.</li><li>- TMR reported as alternative with success but greater technical demands.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Article 2: Kentucky Board of Pharmacy Board Authorized Protocols (BAPs)</strong><br><em>Retrospective cohort evaluation of pharmacist-managed UTI, GAS, COVID-19</em></summary>
            <div>
                <ul><li>- Focus: compare clinical outcomes of pharmacist-managed BAP care for <b>UTI, GAS, and COVID-19</b> to traditional provider outcomes from literature/comparator rates.</li><li>- Rationale: HRSA-identified primary care shortages; Kentucky expanded pharmacist scope via BAPs to increase access.</li><li>- Design: retrospective EHR cohort across UK Pharmacist Care Clinic locations; data window <q><b>Oct 1, 2022 - Sep 30, 2025</b></q>.</li></ul>
                
        <details>
            <summary><strong>Background & rationale</strong></summary>
            <div>
                <ul><li>- National gap: <q><b>78 million</b></q> people in primary care HPSAs; > <q><b>13,000</b></q> providers needed (HRSA, May 2025).</li><li>- Kentucky: > <q><b>1,000</b></q> primary care HPSAs; pharmacists can expand access via state BAPs.</li><li>- Existing evidence: VA pharmacist practitioners manage chronic disease well; acute POCT pharmacist data limited but international studies suggest comparable outcomes and cost benefits.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Overall specific aims & hypotheses</strong></summary>
            <div>
                <ul><li>- Aim: evaluate whether pharmacist-delivered care under BAPs yields <b>similar clinical outcomes</b> to traditional providers for UTI, GAS, and COVID-19.</li><li>- Hypothesis: pharmacist-managed BAP care will have outcomes comparable to traditional care for each disease state.</li><li>- Three-manuscript approach: one manuscript per disease state focusing on disease-specific outcomes.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Study population & design details</strong></summary>
            <div>
                <ul><li>- Inclusion: patients treated under relevant BAP at UK Healthcare locations during study window; repeat encounters allowed.</li><li>- No broad exclusion criteria due to retrospective design; each BAP enforces its own eligibility rules.</li><li>- Data sources: EHR extraction with some manual chart review; no blinding required; expedited IRB likely.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>UTI BAP: eligibility & exclusions</strong></summary>
            <div>
                <ul><li>- Inclusion: female age <q><b>18-64 years</b></q>, prior UTI history, at least one UTI symptom, positive POCT for nitrites+leukocytes.</li><li>- Major exclusions: male, age ≥ <q><b>65</b></q>, pregnancy, post-menopausal, immunocompromised, structural urinary abnormalities, pyelonephritis signs, recent UTI treatment (within 1 month), recurrent UTIs (≥4/year).</li><li>- Rationale: select uncomplicated UTI population to match expected cure-rate comparators.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>UTI BAP: permitted antibiotics & efficacy comparators</strong></summary>
            <div>
                <ul><li>- Allowed agents/doses: <b><u>nitrofurantoin 100 mg PO BID x5d</u></b>; <b><u>SMX-TMP 800/160 mg PO BID x3d</u></b>; <b><u>fosfomycin 3 g PO once</u></b>.</li><li>- Comparator clinical cure rates used for nitrofurantoin: <q><b>79-92%</b></q> (literature-based per agent and population).</li><li>- Primary outcome: clinical cure = no repeat UTI testing/treatment within <q><b>7 days</b></q> post-index visit (EHR-determined).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>UTI BAP: secondary outcomes & analysis</strong></summary>
            <div>
                <ul><li>- Secondary outcomes: time to prescription pick-up; adverse events requiring follow-up within <q><b>7 days</b></q>.</li><li>- Statistical test: Student’s t-test for primary comparisons vs literature/comparator rates.</li><li>- Note: antimicrobial resistance differences require agent-specific comparator benchmarking.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>GAS BAP: eligibility & exclusions</strong></summary>
            <div>
                <ul><li>- Inclusion: age ≥ <q><b>5 years</b></q> (parental consent for minors), symptoms consistent with GAS, positive POCT for GAS.</li><li>- Exclusions: age <5, pregnancy/breastfeeding, immunocompromised, prior rheumatic fever, recent antibiotics, clinically unstable (severe vitals/AMS), signs suggesting viral illness.</li><li>- Rationale: ensure appropriate antibiotic prescribing and safety.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>GAS BAP: therapy, outcome definitions</strong></summary>
            <div>
                <ul><li>- Primary agent: <b><u>amoxicillin</u></b> (study includes only amoxicillin-treated patients for analysis).</li><li>- Primary outcome: clinical cure defined as no repeat testing/treatment within <q><b>7 days</b></q>. Comparator failure rate from small pediatric study ~ <q><b>4.75%</b></q> at day 6 used for benchmarking.</li><li>- Secondary outcomes: time to pick-up and adverse events within <q><b>7 days</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>COVID-19 BAP (nirmatrelvir/ritonavir) eligibility</strong></summary>
            <div>
                <ul><li>- Inclusion: age ≥ <q><b>12 years</b></q>, weight ≥ <q><b>40 kg</b></q>, positive SARS-CoV-2 test within <q><b>5 days</b></q>, at risk for progression, ability to assess renal/hepatic function and DDIs.</li><li>- Exclusions: severe renal impairment (eGFR < <q><b>30 ml/min</b></q>), severe hepatic impairment (Child-Pugh C), major DDIs, currently hospitalized.</li><li>- Only patients who actually received nirmatrelvir/ritonavir are included in analysis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>COVID-19 BAP: outcomes & comparator effectiveness</strong></summary>
            <div>
                <ul><li>- Primary outcome: hospitalization or death within <q><b>30 days</b></q> of positive test (EHR-determined).</li><li>- Literature effectiveness: nirmatrelvir/ritonavir showed estimated effectiveness ~ <q><b>79.6%</b></q> overall; subgroup up to <q><b>89.6%</b></q> if dispensed same day.</li><li>- For this study, comparator effectiveness chosen as <q><b>80%</b></q> for benchmarking.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Data handling, outcomes definition & analysis</strong></summary>
            <div>
                <ul><li>- Primary outcomes for each BAP: clinical cure within <q><b>7 days</b></q> for UTI & GAS; <q><b>30-day</b></q> hospitalization/death for COVID-19.</li><li>- Secondary outcomes: time to pick-up; 7-day adverse events requiring follow-up.</li><li>- Analysis: Student’s t-test for primary comparisons; descriptive statistics for demographics and visit-level analyses.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Key numeric thresholds & drug regimens (quick reference)</strong></summary>
            <div>
                <ul><li>- UTI regulated regimens: <q><b>nitrofurantoin 100 mg PO BID x5d</b></q>; <q><b>SMX-TMP 800/160 mg PO BID x3d</b></q>; <q><b>fosfomycin 3 g PO once</b></q>.</li><li>- GAS: age threshold <q><b>5 years</b></q>; comparator failure rate used <q><b>4.75%</b></q>.</li><li>- COVID-19: inclusion window <q><b>5 days</b></q>; comparator effectiveness <q><b>80%</b></q> used for study benchmarks.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Limitations, biases & generalizability</strong></summary>
            <div>
                <ul><li>- Retrospective design -> potential for selection bias, unmeasured confounding, and missing data; some variables need manual chart review.</li><li>- Comparators often literature-based rather than contemporaneous physician-managed cohorts -> potential temporal or population differences.</li><li>- BAP implementation heterogeneity across sites may limit external generalizability.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Practical implications & safety considerations</strong></summary>
            <div>
                <ul><li>- Pharmacist-driven BAPs can increase access in HPSAs but require strict eligibility, DDI screening (esp. nirmatrelvir/ritonavir), and lab capability for renal/hepatic assessment.</li><li>- Monitoring: ensure mechanism to capture adverse events and timely follow-up; document time-to-dispense to maximize effectiveness (noted benefit if same-day dispensing for COVID-19).</li><li>- Policy note: BAPs are state-level scope expansions; outcomes data needed to inform broader legislative changes.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
